Compugen Ltd - ESG Rating & Company Profile powered by AI
This Disclosure rating covers 17 UN Sustainable Development Goals including: 'Clean Water & Sanitation', 'Reduced Inequalities' and 'Life on Land'. Other corporations in the rating industry group for Compugen Ltd are shown below. The webpage displays a zero-cost Sustainability analysis for Compugen Ltd.
Compugen Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.8; made up of an environmental score of 4.8, social score of 6.4 and governance score of 2.7.
4.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1082 | Respiratorius AB (publ) | 4.9 | High |
| 1082 | Shenzhen Chipscreen Biosciences Co Ltd | 4.9 | High |
| 1121 | Compugen Ltd | 4.8 | High |
| 1121 | Heat Biologics Inc | 4.8 | High |
| 1121 | Curis Inc | 4.8 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Compugen Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Compugen Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Compugen Ltd report the average age of the workforce?
Sign up for free to unlockDoes Compugen Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Compugen Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Compugen Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Compugen Ltd offer flexible work?
Sign up for free to unlockDoes Compugen Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Compugen Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Compugen Ltd conduct supply chain audits?
Sign up for free to unlockDoes Compugen Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Compugen Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Compugen Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Compugen Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Compugen Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Compugen Ltd disclose water use targets?
Sign up for free to unlockDoes Compugen Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Compugen Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Compugen Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Compugen Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Compugen Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Compugen Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Compugen Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Compugen Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Compugen Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Compugen Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Compugen Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Compugen Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Compugen Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Compugen Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Compugen Ltd disclose its waste policy?
Sign up for free to unlockDoes Compugen Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Compugen Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Compugen Ltd disclose energy use targets?
Sign up for free to unlockDoes Compugen Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Compugen Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Compugen Ltd
These potential risks are based on the size, segment and geographies of the company.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.